News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
Merck & Co., Inc. CEO: Acquisitions are Key Priority for 2009
January 8, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Merck & Co.'s (MRK 29.39, -0.10, -0.3%) leader said the drug maker has the resources to make significant acquisitions, but if the company doesn't make big purchases it will return cash to shareholders through dividends or share buybacks.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Merck & Co.
MORE ON THIS TOPIC
Podcast
CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP
July 2, 2025
·
1 min read
·
Heather McKenzie
Mergers & acquisitions
AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies
June 30, 2025
·
2 min read
·
Dan Samorodnitsky
Alzheimer’s disease
Alzheimer’s Deals Surged 780% After Leqembi, Kisunla Broke Approval Stalemate
June 30, 2025
·
2 min read
·
Annalee Armstrong
Layoffs
Sage Sacks Entire Staff After Supernus Buyout
June 30, 2025
·
1 min read
·
Tristan Manalac